Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Tipos de Cancer / Cáncer del Seno / Opciones Del Tratamiento /
| Surgery and Radiotherapy for Breast Cancer: A Look at the Studies In December of 2005, the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) published the combined results of 78 clinical trials evaluating radiation therapy and surgery in breast cancer patients.The group has published updates of this data every 5 years, and this publication represents 15 years of follow-up. The paper is jam-packed with |
| Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial Reviewers: John Han-Chih Chang, MD Source: Lancet 1999 May 15; Volume 353(Number 9165): 1641-8Background/Discussion/CritiqueThe New England Journal publications in 1997 from Denmark and Canada demonstrated a survival benefit for postmastectomy radiation therapy (RT) in premenopausal women with high risk breast cancer. The benefits of tamoxifen in |
| Adjuvant Radiotherapy in Pre-Menopausal Women with Breast Cancer Reviewers: John Han-Chih Chang, MD and Ken Blank, MD Source: N Engl J Med. 1997 Oct 2;337(14):956-62.Possibly more than any other cancer, the treatment of breast cancer has evolved over the past twenty years. Surgery to remove the entire breast (simple, modified and radical mastectomy) has been largely replaced by breast conserving surgery |
| Preliminary Analysis of Radiotherapy Data from CALGB 9082: Variability of Treatment Fields for Local/Regional Breast Cancer and the Impact of High Dose Chemotherapy on the Ability to Deliver Radiation Therapy Presenter: Lawrence B. Marks, M.D. Affiliation: Duke University/CALGB/SWOG Summary:Positive contributions of radiotherapy (RT) and chemotherapy in patients with high-risk breast cancer are well documented, but the sequencing of these modalities and dosage of chemotherapy in such patients remains controversial. This offering examines the effect |
| Timescale of Evolution of Late Radiation Injury after Postoperative Radiotherapy of Breast Cancer Patients Presenter: Silvia Johansson Affiliation: Umea University Hospital, Sweden Summary:Most of the modern randomized trials in breast cancer document toxicity associated with treatment, but none document these toxicities over the scale of decades. These data are important because many women are diagnosed with breast cancer at a relatively young age, |
| Complications and Patient Satisfaction Following Breast Implant Reconstruction with and without Radiotherapy Presenter: Edith Krueger Affiliation: University of Michigan and William Beaumont Hospital Background:Women undergoing breast implant reconstruction after mastectomy may also require radiation therapy, but data regarding complications and patient satisfaction are limited. The Michigan Breast Reconstruction Outcome Study (MBROS) was designed to |
| Comparison Of Lumpectomy Plus Tamoxifen With And Without Radiotherapy (RT) In Women 70 Years Of Age Or Older Who Have Clinical Stage I, Estrogen Receptor Positive (ER+) Breast Carcinoma Presenter: Kevin S. Hughes Affiliation: Massachusetts General Hospital Background: No survival impact of RT from previous studies. Tumor in this group of pts grow slowly, therefore, less time at risk. This study is designed to assess, in this population, whether RT, when added to tamoxifen: 1) decreases locoregional recurrence, 2) |
| Locoregional Failure of Post-Mastectomy Patients Who Had 1-3 Positive Axillary Lymph Nodes without Adjuvant Radiotherapy Presenter: C. Cheng Presenter's Affiliation: Sun Yat-Sen Cancer Center Type of Session: Scientific Background Post-mastectomy radiation is routinely given for patients with 4 or more positive lymph nodes to reduce locoregional failure. However, optimal adjuvant treatment for those with 1-3 positive lymph nodes is debated. This study was |
| Randomized Study Comparing Adjuvant Radiotherapy (RT) with Concomitant Chemotherapy (CT) Versus Sequential Treatment After Conservative Surgery for Patients with Stages I and II Breast Carcinoma Presenter: Gilles. CalaisPresenter's Affiliation: Department of Oncology Radiotherapy, CHU, Tours, FranceType of Session: ScientificBackground Both whole breast irradiation and chemotherapy are often indicated after conservative surgery for early stage breast cancer. However, the sequencing of CT and RT after conservative surgery in this group is |
| Brachytherapy Alone Versus Whole Breast Radiotherapy After Breast Conserving Surgery: 5-year Results of a Phase I-II Study and Interim Findings of a Phase III Trial Presenter: Csaba PolgarPresenter's Affiliation: Department of Radiotherapy, National Institute of Oncology, Budapest, HungaryType of Session: ScientificBackground Partial breast irradiation (PBI) has recently received alot of attention, especially since the FDA approval of a balloon-type brachytherapy applicator. This therapeutic approach is |
| Patterns of Recurrence by Sequence of Chemotherapy and Radiotherapy in Early Stage Breast Cancer Presenter: Lori Pierce, M.D.Presenter's Affiliation: University of MichiganType of Session: ScientificBackground The impact of sequencing of chemotherapy and radiation therapy (RT) for breast conservation therapy (BCT) is unclear. A previous large randomized trial of the sequencing of chemotherapy and RT following surgery showed no difference in |
| A Phase I Clinical Trial Assessing Temozolamide and Tamoxifen with Concomitant Radiotherapy for the Treatment of High-Grade Gliomas Presenter: T.W. FlanneryPresenter's Affiliation: Radiation Oncology, University of Maryland, Baltimore, MDType of Session: ScientificBackground One of the many recent advances in the management of high grade gliomas includes the slight survival advantage seen with the use of concurrent temozolamide and radiation for glioblastoma multiforme (GBM). |
| ASTRO Patient Summary: A Phase I Clinical Trial Assessing Temozolamide and Tamoxifen with Concomitant Radiotherapy for the Treatment of High-Grade Gliomas A Phase I Clinical Trial Assessing Temozolamide and Tamoxifen with Concomitant Radiotherapy for the Treatment of High-Grade Gliomas There are limited therapies available for patients with high-grade gliomas. One particular problem is finding medications that are able to cross the blood-brain barrier in amounts significant enough to treat the |
| Phase III Randomized Study of Intensity Modulated Radiation Therapy vs. Standard Wedging Adjuvant Breast Radiotherapy Presenter: Jean-Philippe Pignol, M.D.Presenter's Affiliation: Sunnybrook and Women's College Health Sciences Centre, Toronto , Ontario , CanadaType of Session: PlenaryBackground The current standard adjuvant treatment of localized breast cancer is whole breast radiotherapy Prior to using modern 3-D planning techniques, opposed tangent |
| The 2006 Worldwide Overview of the Effects of Local Treatments for Early Breast Cancer On Long-term Outcome? "Meta-analysis of the Randomized Trials of Radiotherapy After Mastectomy With Axillary Clearance" Presenter: Paul McGale, PhDPresenter's Affiliation: Clinical Trial Service Unit, United KingdomType of Session: PlenaryBackground Randomized trials have shown that post-mastectomy radiation therapy ( PMRT ) confers both a local control and survival benefit in certain patient populations. It is generally accepted that patients with 4 or |
| The 2006 Worldwide Overview of the Effects of Local Treatments for Early Breast Cancer On Long-term Outcome? "Meta-analysis of the Randomized Trials of Radiotherapy After Mastectomy With Axillary Clearance" The 2006 Worldwide Overview of the Effects of Local Treatments for Early Breast Cancer On Long-term Outcome? "Meta-analysis of the Randomized Trials of Radiotherapy After Mastectomy With Axillary Clearance" It is well understood that radiation therapy after mastectomy ( PMRT ) improves survival and decreases recurrence rates in women |
| Prospective Trial of Individual Optimal Positioning (Prone Versus Supine) for Whole Breast Radiotherapy: Results of the First 168 Patients Presenter: Silvia C. Formenti, MDPresenter's Affiliation: New York University Medical CenterType of Session: ScientificBackground External beam radiation therapy as part of breast conservation therapy for early stage breast cancer has traditionally used tangential fields to treat the whole breast of patients in the supine position. Newer |
| QRRO 2007 Practice Survey Documents Dramatic Technical Changes in How Radiotherapy for Operable Breast Cancer is Delivered Authors: J.R. White1, N. Khalid2, M.L. Tao3, L.J. Pierce4, A. DeRobertis5, C. Crozier2, J.B. Owen2 and J.F. Wilson1 Institution: 1Medical College of Wisconsin, Milwaukee, WI 2American College of Radiology, Philadelphia, PA 3Epic Care, Orinda, CA 4University of Michigan Medical School, Ann Arbor, MI 5Massachusetts General |
| The Effect of Radiotherapy on Local Regional Recurrence among Patients with Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Authors: C. E. Fasola, K. D. Godette, M. W. McDonald, R. M. O'Regan, A. B. Zelnak, J. C. Landry, M. A. Torres. Affiliations: Emory University School of Medicine, Atlanta, GA. Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. Department of Radiation Oncology, Indiana University School of Medicine, |
Dr. Giantonio discusses the importance of oncology clinical trials and clarifies some myths about studies. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

